Inventor · disambiguated record
Cohava Gelber
Also filed as: GELBER COHAVA
20 granted patents·19 pending applications·154 citations·filing 1999–2025
94Inventor score
Files withSERPIN PHARMA LLC14IMMUNOCELLULAR THERAPEUTICS LT5MANNKIND CORP5GELBER COHAVA3AMERICAN TYPE CULTURE COLLECTION2
Top patents by PatentIndex Score
39 records- 0194US6991779B2Compositions for treatment or prevention of bioterrorismMANNKIND CORP·Filed 2003·Granted Jan 31, 2006·60 cites·15 claims
- 0289US7951776B2Methods for treatment of type 1 diabetesAMERICAN TYPE CULTURE COLLECTION·Filed 2009·Granted May 31, 2011·9 cites·19 claims
- 0384US7951382B2Methods for treatment of type 2 diabetesAMERICAN TYPE CULTURE COLLECTION·Filed 2010·Granted May 31, 2011·9 cites·6 claims
- 0483US7435415B2Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC)IMMUNOCELLULAR THERAPEUTICS LT·Filed 2004·Granted Oct 14, 2008·15 cites·3 claims
- 0582US10214562B2Peptides and methods of using sameSERPIN PHARMA LLC·Filed 2015·Granted Feb 26, 2019·3 cites·18 claims
- 0682US7687607B2Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLS)IMMUNOCELLULAR THERAPEUTICS LT·Filed 2008·Granted Mar 30, 2010·4 cites·6 claims
- 0781US10899797B2Peptides and methods of using sameSERPIN PHARMA LLC·Filed 2019·Granted Jan 26, 2021·1 cites·15 claims
- 0881US8975224B2Peptides and methods of using sameSERPIN PHARMA LLC·Filed 2013·Granted Mar 10, 2015·4 cites·8 claims
- 0981US2025228922A1Methods for treatment of diseasesSERPIN PHARMA LLC·Filed 2024·Application pending·0 cites
- 1080US11779630B2Peptides and methods of using the sameSERPIN PHARMA LLC·Filed 2021·Granted Oct 10, 2023·1 cites·6 claims
- 1180US9951104B2Peptides and methods of using sameSERPIN PHARMA LLC·Filed 2013·Granted Apr 24, 2018·3 cites·9 claims
- 1279US6376654B1Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereofMOLECULAR DISCOVERIES LLC·Filed 1999·Granted Apr 23, 2002·34 cites·5 claims
- 1379US2025346632A1Serpin peptides and methods of using the sameSERPIN PHARMA LLC·Filed 2025·Application pending·0 cites
- 1478US7691376B2Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereofIMMUNOCELLULAR THERAPEUTICS LT·Filed 2007·Granted Apr 6, 2010·2 cites·22 claims
- 1574US12291581B2Serpin peptides and methods of using the sameSERPIN PHARMA LLC·Filed 2020·Granted May 6, 2025·0 cites·13 claims
- 1674US11020462B2Methods for treatment of diseasesSERPIN PHARMA LLC·Filed 2016·Granted Jun 1, 2021·1 cites·16 claims
- 1774US7183389B2Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC)MOLECULAR DISCOVERIES LLC·Filed 2001·Granted Feb 27, 2007·6 cites·2 claims
- 1873US2009232891A1Cell Transport Compositions and Uses ThereofGELBER COHAVA·Filed 2009·Application pending·0 cites
- 1966US2021369822A1Methods for treatment of diseasesSERPIN PHARMA LLC·Filed 2021·Application pending·0 cites
- 2062US2004038865A1Cell transport compositions and uses thereofMANNKIND CORP·Filed 2003·Application pending·0 cites
- 2161US2023406906A1Serpin peptides and methods of using the sameSERPIN PHARMA LLC·Filed 2023·Application pending·0 cites
- 2261US2024261364A1Peptides and methods of using the sameSERPIN PHARMA LLC·Filed 2023·Application pending·0 cites
- 2360US2009203602A1Compositions and methods for diagnosis and treatment of type 2 diabetesGELBER COHAVA·Filed 2009·Application pending·0 cites
- 2459US7498129B2Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereofIMMUNOCELLULAR THERAPEUTICS LT·Filed 2006·Granted Mar 3, 2009·0 cites·5 claims
- 2559US7435554B2Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC)IMMUNOCELLULAR THERAPEUTICS LT·Filed 2004·Granted Oct 14, 2008·0 cites·9 claims
- 2659US2025161419A1Serpin peptides and methods of using the sameSERPIN PHARMA LLC·Filed 2022·Application pending·0 cites
- 2758US6986891B2Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereofMOLECULAR DISCOVERIES L L C·Filed 2001·Granted Jan 17, 2006·1 cites·25 claims
- 2857US2015290132A1Cell Transport Compositions and Uses ThereofMANNKIND CORP·Filed 2015·Application pending·0 cites
- 2953US2025353898A1Serpin peptide derivatives and methods of using the sameSERPIN PHARMA LLC·Filed 2023·Application pending·0 cites
- 3053US2006153778A1Methods and compositions for minimizing accrual of inhalable insulin in the lungsMANNKIND CORP·Filed 2006·Application pending·0 cites
- 3150US11623953B2Antibody constructs and methods of treating cancerCAERUS THERAPEUTICS INC·Filed 2018·Granted Apr 11, 2023·0 cites·20 claims
- 3250US7226750B1Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereofMOLECULAR DISCOVERIES INC·Filed 2000·Granted Jun 5, 2007·1 cites·14 claims
- 3348US2022119478A1Advanced chimeric antigen receptor vectors for targeting solid tumorsCAERUS THERAPEUTICS CORP·Filed 2020·Application pending·0 cites
- 3448US2008300170A1Compositions and methods for diagnosis and treatment for type 2 diabetesGELBER COHAVA·Filed 2007·Application pending·0 cites
- 3547US2023138520A1Humanized antibodies specific for myeloma and ovarian cancer cellsCAERUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3645US2020048321A1Pantids for treatment of autoimmune disordersORPHEUS BIOSCIENCE INC·Filed 2018·Application pending·0 cites
- 3745US2004166141A1Methods and devices for modulating the immune responseFiled 2004·Application pending·0 cites
- 3844US2008260838A1Glucagon-like peptide 1 (glp-1) pharmaceutical formulationsMANNKIND CORP·Filed 2007·Application pending·0 cites
- 3936US2010267052A1Compositions and methods for diagnosis and treatment of type 2 diabetesAMERICAN TYPE CULTURE COLLECTI·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cohava Gelber files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →